Short-Term Debt
The latest quarterly short-term debt is $18.60 Million with a quarter-over-quarter change of -16.22%. Short-term debt includes all borrowings and debt obligations due within one year, including the current portion of long-term debt, commercial paper, and credit facilities.
PODD Short-Term Debt
Reported quarterly short-term debt; no daily interpolation.
Current Short-Term Debt
$18.60M
$18.60 Million
Quarter-over-Quarter Change
-16.22%
vs. $22.20M prior quarter
Historical Data
80
Quarters of data available
Quarterly Short-Term Debt History
| Period | Short-Term Debt | QoQ Change | % Change |
|---|---|---|---|
| Q1 2026 | $18.60M | $-3.60M | -16.22% |
| Q4 2025 | $22.20M | $-74.20M | -76.97% |
| Q3 2025 | $96.40M | $-382.00M | -79.85% |
| Q2 2025 | $478.40M | +$395.30M | +475.69% |
| Q1 2025 | $83.10M | $-2.80M | -3.26% |
| Q4 2024 | $85.90M | +$43.90M | +104.52% |
| Q3 2024 | $42.00M | +$4.10M | +10.82% |
| Q2 2024 | $37.90M | $-1.00M | -2.57% |
| Q1 2024 | $38.90M | $-14.00M | -26.47% |
| Q4 2023 | $52.90M | +$3.10M | +6.22% |
| Q3 2023 | $49.80M | +$20.60M | +70.55% |
| Q2 2023 | $29.20M | +$1.40M | +5.04% |
| Q1 2023 | $27.80M | $-3.30M | -10.61% |
| Q4 2022 | $31.10M | +$4.20M | +15.61% |
| Q3 2022 | $26.90M | +$600,000 | +2.28% |
| Q2 2022 | $26.30M | +$600,000 | +2.33% |
| Q1 2022 | $25.70M | $-4.40M | -14.62% |
| Q4 2021 | $30.10M | +$1.20M | +4.15% |
| Q3 2021 | $28.90M | +$8.00M | +38.28% |
| Q2 2021 | $20.90M | +$5.20M | +33.12% |
| Q1 2021 | $15.70M | $-4.80M | -23.41% |
| Q4 2020 | $20.50M | +$20.50M | — |
| Q3 2020 | $0 | +$0 | — |
| Q2 2020 | $0 | +$0 | — |
| Q1 2020 | $0 | $-3.60M | -100.00% |
| Q4 2019 | $3.60M | +$1.26M | +53.78% |
| Q3 2019 | $2.34M | +$8,000 | +0.34% |
| Q2 2019 | $2.33M | +$18,000 | +0.78% |
| Q1 2019 | $2.31M | +$2.31M | — |
| Q4 2018 | $0 | +$0 | — |
| Q3 2018 | $0 | +$0 | — |
| Q2 2018 | $0 | $-3.45M | -100.00% |
| Q1 2018 | $3.45M | +$3.45M | — |
| Q4 2017 | $0 | +$0 | — |
| Q3 2017 | $0 | +$0 | — |
| Q2 2017 | $0 | +$0 | — |
| Q1 2017 | $0 | $-269,000 | -100.00% |
| Q4 2016 | $269,000 | $-792,000 | -74.65% |
| Q3 2016 | $1.06M | +$1.06M | — |
| Q2 2016 | $0 | +$0 | — |
| Q1 2016 | $0 | +$0 | — |
| Q4 2015 | $0 | +$0 | — |
| Q3 2015 | $0 | +$0 | — |
| Q2 2015 | $0 | +$0 | — |
| Q1 2015 | $0 | +$0 | — |
| Q4 2014 | $0 | +$0 | — |
| Q3 2014 | $0 | $-23.87M | -100.00% |
| Q2 2014 | $23.87M | +$23.87M | — |
| Q1 2014 | $0 | +$0 | — |
| Q4 2013 | $0 | +$0 | — |
| Q3 2013 | $0 | +$0 | — |
| Q2 2013 | $0 | $-14.73M | -100.00% |
| Q1 2013 | $14.73M | +$304,000 | +2.11% |
| Q4 2012 | $14.43M | +$295,000 | +2.09% |
| Q3 2012 | $14.13M | +$285,000 | +2.06% |
| Q2 2012 | $13.85M | +$13.85M | — |
| Q1 2012 | $0 | +$0 | — |
| Q4 2011 | $0 | +$0 | — |
| Q3 2011 | $0 | +$0 | — |
| Q2 2011 | $0 | +$0 | — |
| Q1 2011 | $0 | +$0 | — |
| Q4 2010 | $0 | +$0 | — |
| Q3 2010 | $0 | +$0 | — |
| Q2 2010 | $0 | +$0 | — |
| Q1 2010 | $0 | +$0 | — |
| Q4 2009 | $0 | +$0 | — |
| Q3 2009 | $0 | +$0 | — |
| Q2 2009 | $0 | +$0 | — |
| Q1 2009 | $0 | +$0 | — |
| Q4 2008 | $0 | +$0 | — |
| Q3 2008 | $0 | +$0 | — |
| Q2 2008 | $0 | $-10.67M | -100.00% |
| Q1 2008 | $10.67M | $-1,000 | -0.01% |
| Q4 2007 | $10.67M | +$0 | 0.00% |
| Q3 2007 | $10.67M | +$2.73M | +34.34% |
| Q2 2007 | $7.94M | $-21.28M | -72.82% |
| Q1 2007 | $29.23M | +$3,000 | +0.01% |
| Q4 2006 | $29.22M | +$26.57M | +1003.55% |
| Q3 2006 | $2.65M | +$1.17M | +79.04% |
| Q4 2005 | $1.48M | — | — |
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy